Investor Relations

Recent News
Jun 23, 2021

Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, granted a stock option to a new employee as approved...

Jun 21, 2021

—Topline data anticipated in Q1 2022 with NDA filing to follow in H2 2022— SAN MATEO, Calif., June 21, 2021 /CNW/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company...

Jun 14, 2021

--Chief Medical Officer Dr. Barbara Klencke, to be joined by leading myelofibrosis experts Drs. Aaron Gerds, Stephen Oh and Srdan Verstovsek-- SAN MATEO, Calif., June 14, 2021 /CNW/ - Sierra...

View all news releases

Investor Enquiries

Dede Sheel
Vice President, Investor Relations
investors@sierraoncology.com

Sign up for investor alerts